Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 11/20 | 0.53 |
| ▸ | HTR2A | P28223 | 2/20 | 0.46 |
| ▸ | HTR2C | P28335 | 2/20 | 0.46 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1049671 | 0.91 | HTR7 (0.51) | HTR7HTR2AHTR2CHTR6MCL1 | |
| SCHEMBL1612942 | 0.87 | HTR2C (0.55) | HTR7HTR2AHTR2CHTR6DYRK1A | |
| SCHEMBL24143341 | 0.83 | HTR7 (0.53) | HTR7HTR2AHTR2CHTR6PRMT5 | |
| SCHEMBL18239699 | 0.81 | HTR7 (0.57) | HTR7HTR2AHTR2CHTR6PRMT5 | |
| SCHEMBL22946242 | 0.81 | HTR2C (0.68) | HTR7HTR2AHTR2CMTNR1AMTNR1B | |
| SCHEMBL31435621 | 0.79 | HTR2C (0.50) | HTR7HTR2AHTR2CDYRK1APRMT5 | |
| SCHEMBL31559241 | 0.79 | PSMB1 (0.50) | DYRK1A | |
| SCHEMBL9092781 | 0.79 | HTR7 (0.49) | HTR7HTR2AHTR2CHTR6PRMT5 | |
| SCHEMBL30041141 | 0.78 | MCL1 (0.55) | HTR7HTR2AHTR2CMTNR1AMTNR1B | |
| SCHEMBL25037435 | 0.78 | MCL1 (0.53) | HTR7HTR2AHTR2CMTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025245484-A1 | FOXN1 ACTIVATORS | THYMOFOX INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| US-20180148429-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2018-05-31 | — | — | US | disclosed |
| US-20180148429-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2018-05-31 | — | — | US | disclosed |
| US-20180148429-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2018-05-31 | — | — | US | disclosed |
| WO-2016180536-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2016-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148429-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | BRCA1, NQO2, NQO1 | HTR7 3745/4885HTR2A 2968/4885HTR2C 3274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.